AltaRex Corp., National Institutes of Health deal

AXO licensed a monoclonal antibody (MAb) from the NIH that AXO will develop under its Antibody-based Immunotherapy (AIT) platform to treat ovarian and other cancers. AXO's OvaRex MAb to treat ovarian cancer is in Phase IIb development. ...